bcbs fep glp-1 coverage Drugs: What Employers Need to Know Insurance coverage just changed for

Glucagon-like peptide-1 (GLP-1) is a gut-derived hormone essential for maintaining glucose homeostasis through multiple physiological pathways: triggering insulin release, inhibiting glucagon secretion, delaying gastric emptying, enhancing feelings of fullness, and suppressing appetite

Three very different formulas

However, from one of the leading prescribers in Australia with over 3,000 patients, painstaking research, user surveys, and interviews, we prepared this guide

My personal experience with low-dose semaglutide (GLP-1) in Perimen

As expanded insurance coverage is expected to significantly improve access to costly therapies, substantial changes are anticipated across both the obesity treatment market and broader healthcare paradigms.

In February 2026, the FDA publicly announced its intent to take action targeting mass-marketed, non-FDA-approved compounded GLP1 products, emphasizing that promotional claims implying equivalence to FDAapproved drugs can trigger enforcement risk